Olaratumab for advanced soft tissue sarcoma
| Autor: | Mark Agulnik, Alexander Tobias, Michael P. O’Brien |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Receptor Platelet-Derived Growth Factor alpha medicine.drug_class Pharmacology Disease-Free Survival Tyrosine-kinase inhibitor 03 medical and health sciences 0302 clinical medicine Growth factor receptor Antineoplastic Combined Chemotherapy Protocols medicine Animals Humans Pharmacology (medical) Doxorubicin General Pharmacology Toxicology and Pharmaceutics Randomized Controlled Trials as Topic business.industry Soft tissue sarcoma Antibodies Monoclonal Soft tissue Sarcoma General Medicine medicine.disease Survival Rate 030104 developmental biology 030220 oncology & carcinogenesis Cancer research business Tyrosine kinase Olaratumab medicine.drug |
| Zdroj: | Expert Review of Clinical Pharmacology. 10:699-705 |
| ISSN: | 1751-2441 1751-2433 |
| Popis: | Olaratumab is a humanized IgG1 monoclonal antibody that blocks the platelet-derived growth factor receptor alpha (PDGFRα). Its antagonistic behavior inhibits the receptor's tyrosine kinase activity, thereby, turning off the downstream signaling cascades responsible for soft tissue sarcoma tumorigenesis. In October 2016, olaratumab received Food and Drug Administration (FDA) approval for its use in combination with doxorubicin for treatment of advanced soft tissue sarcoma. Areas covered: This drug profile takes a comprehensive look at the clinical studies leading to FDA approval of olaratumab as well as its safety and efficacy as a front-line treatment option for sarcoma patients. The literature search was primarily conducted using PubMed. Expert commentary: The combination of olaratumab plus doxorubicin has provided a new front-line therapeutic option for soft tissue sarcoma patients. An open-label phase Ib and randomized phase II trial in patients with advanced soft tissue sarcoma demonstrated that the addition of olaratumab to doxorubicin prolonged progression-free survival by 2.5 months and overall survival by 11.8 months when compared to doxorubicin alone. Of importance, this clinically meaningful increase in overall survival did not come at the expense of a significantly greater number of toxicities. A phase III confirmatory trial (ClinicalTrials.gov Identifier NCT02451943) will be completed in 2020. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|